{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:47:43Z","timestamp":1791380863798,"version":"4.3.3"},"reference-count":20,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>An association of deletions in the IKZF1 gene (IKZF1del) with poor prognosis in acute lymphoblastic leukemia (ALL) has been demonstrated. Additional deletions in other genes (IKZF1plus) define different IKZF1del subsets. We analyzed the influence of IKZF1del and\/or IKZF1plus in the survival of children with ALL. From October 2009 to July 2021, 1055 bone marrow samples from patients with ALL were processed by Multiplex ligation-dependent probe amplification (MLPA). Of them, 28 patients died during induction and 4 were lost-in-follow-up, resulting in an eligible 1023 cases. All patients were treated according to ALLIC-BFM-2009-protocol. Patients were classified into three subsets: IKZF1not-deleted (IKZFF1not-del), IKZF1deleted (IKZF1del) and IKZF1del plus deletion of PAX5, CDKN2A, CDKN2B and\/or alterations in CRLF2 with ERG-not-deleted (IKZF1plus). The LFSp and SE were calculated with the Kaplan\u2013Meier calculation and compared with a log-rank test. From the 1023 eligible patients, 835 (81.6%) were defined as IKZF1not-del, 94 (9.2%) as IKZF1del and 94 (9.2%) as IKZF1plus. Of them, 100 (9.8%) corresponded to Standard-Risk (SRG), 629 (61.5%) to Intermediate-Risk (IRG) and 294 (28.7%) to High-Risk (HRG) groups. LFSp(SE) was 7 5(2)% for IKZF1not-del, 51 (6)% for IKZF1del and 48 (6)% for IKZF1plus (p-value &lt; 0.00001). LFSp(SE) according to the risk groups was: in SRG, 91 (4)% for IKZF1not-del, 50 (35)% IKZF1del and 100% IKZF1plus (p-value = ns); in IRG, 77 (2)% IKZF1not-del, 61 (10)% IKZF1del and 54 (7)% IKZF1plus (p-value = 0.0005) and in HRG, 61 (4)% IKZF1not-del, 38 (8)% IKZF1del and 35 (9)% IKZF1plus (p-value = 0.0102). The IKZF1 status defines a population of patients with a poor outcome, mainly in IRG. No differences were observed between IKZF1del versus IKZF1plus. MLPA studies should be incorporated into the risk-group stratification of pediatric ALL.<\/jats:p>","DOI":"10.3390\/cancers14133283","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T10:21:33Z","timestamp":1657016493000},"page":"3283","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Impact of IKZF1 Deletions in the Prognosis of Childhood Acute Lymphoblastic Leukemia in Argentina"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7505-6549","authenticated-orcid":false,"given":"Mar\u00eda Sara","family":"Felice","sequence":"first","affiliation":[{"name":"Hematology and Oncology Department, Hospital de Pediatr\u00eda Juan P. Garrahan, Buenos Aires 1245, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Laura","family":"Rubio","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Department, Hospital de Pediatr\u00eda Juan P. Garrahan, Buenos Aires 1245, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Digiorge","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Department, Hospital de Pediatr\u00eda Juan P. Garrahan, Buenos Aires 1245, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00e1ngeles","family":"Barreda Frank","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Department, Hospital de Pediatr\u00eda Juan P. Garrahan, Buenos Aires 1245, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste Sabrina","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Department, Hospital de Pediatr\u00eda Juan P. Garrahan, Buenos Aires 1245, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam Ruth","family":"Guitter","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Department, Hospital de Pediatr\u00eda Juan P. Garrahan, Buenos Aires 1245, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa Olga","family":"Sajaroff","sequence":"additional","affiliation":[{"name":"Immunology and Rheumatology Department, Hospital de Pediatr\u00eda Juan P. Garrahan, Buenos Aires 1245, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian Germ\u00e1n","family":"S\u00e1nchez La Rosa","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Department, Hospital de Pediatr\u00eda Juan P. Garrahan, Buenos Aires 1245, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8944-7535","authenticated-orcid":false,"given":"Carla Luciana","family":"Pennella","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Department, Hospital de Pediatr\u00eda Juan P. Garrahan, Buenos Aires 1245, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisina Bel\u00e9n","family":"Peruzzo","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Department, Hospital de Pediatr\u00eda Juan P. Garrahan, Buenos Aires 1245, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Alejandra","family":"Deu","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Department, Hospital de Pediatr\u00eda Juan P. Garrahan, Buenos Aires 1245, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Melania","family":"Alfaro","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Department, Hospital de Pediatr\u00eda Juan P. Garrahan, Buenos Aires 1245, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Constanza","family":"Guardia","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Department, Hospital del Ni\u00f1o Jes\u00fas, San Miguel de Tucum\u00e1n, Tucum\u00e1n 4000, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gladys","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Department, Hospital Juan Pablo II, Corrientes 1435, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Angelica","family":"Fern\u00e1ndez Barbieri","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Department, Hospital de Ni\u00f1os de San Isidro, Buenos Aires 1245, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezequiel","family":"Recondo","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Department, Hospital Nacional de Cl\u00ednicas San Mart\u00edn, Buenos Aires 1245, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Soledad","family":"Vides Herrera","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Department, Hospital Eva Per\u00f3n, Catamarca 1435, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanina","family":"Livio","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Department, Hospital Avelino Castel\u00e1n, Resistencia, Chaco 3508, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanza","family":"Arnaiz","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Department, Hospital de Ni\u00f1os Castro Rend\u00f3n, Neuqu\u00e9n 8300, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Romero","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Department, Hospital Alexander Fleming OSEP, Mendoza 5500, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5527-3901","authenticated-orcid":false,"given":"Cristina Noemi","family":"Alonso","sequence":"additional","affiliation":[{"name":"Area of Specialized Laboratories, Hospital de Pediatr\u00eda Prof. Dr. Juan P. Garrahan, Buenos Aires 1245, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Gabriel","family":"Rossi","sequence":"additional","affiliation":[{"name":"Immunology and Rheumatology Department, Hospital de Pediatr\u00eda Juan P. Garrahan, Buenos Aires 1245, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"key":"ref_1","first-page":"2754","article-title":"Intensive Chemotherapy for Childhood Acute Lymphoblastic Leukemia: Results of the Ran-domized Intercontinental Trial ALL IC-BFM 2002","volume":"53","author":"Stary","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.blre.2012.01.001","article-title":"The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia","volume":"26","author":"Moorman","year":"2012","journal-title":"Blood Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1470-2045(10)70066-8","article-title":"Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lympho-blastic leukaemia: Results from the UK Medical Research Council ALL97\/99 randomised trial","volume":"11","author":"Moorman","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/leu.2013.379","article-title":"Highhyperdiploidy among adolescents and adults with acute lymphoblastic leukaemia (ALL): Cytogenetic features, clinical characteristics and outcome","volume":"28","author":"Chilton","year":"2014","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1182\/blood-2015-02-580043","article-title":"Redefining ALL classification: Toward detecting high-risk ALL and implementing precision medicine","volume":"125","author":"Hunger","year":"2015","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3324\/haematol.2015.141101","article-title":"New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia","volume":"101","author":"Moorman","year":"2016","journal-title":"Haematology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Children\u2019s Oncology Group: Deletion ofIKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/bloodadvances.2018025718","article-title":"On behalf of the international BFM study group. Validation of the United Kingdom Copy Number Alteration classifier in 3239 children with B cell precursor acute lymphoblastic leukaemia","volume":"22","author":"Hamadeh","year":"2019","journal-title":"Blood Adv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1200\/JCO.2008.21.6408","article-title":"IKZF1 (Ikaros) Deletions in BCR-ABL1\u2013Positive Acute Lymphoblastic Leukemia Are Associated with Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report","volume":"27","author":"Martinelli","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3324\/haematol.2011.056135","article-title":"IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol","volume":"98","author":"Meissner","year":"2013","journal-title":"Haematologica"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1073\/pnas.0811761106","article-title":"JAK mutations in high-risk childhood acute lymphoblastic leukemia","volume":"106","author":"Mullighan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/leu.2013.282","article-title":"ERG deletion is as-sociated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia","volume":"28","author":"Zaliova","year":"2014","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","article-title":"IKZF1plus Defines a New Minimal Residual Disease\u2013Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"36","author":"Stanulla","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","article-title":"Standarized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease","volume":"13","author":"Macintyre","year":"1999","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1995","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1977.1","article-title":"Design and analysis of randomized clinical trials requiring prolonged observation on each patient. II. Analysis and examples","volume":"35","author":"Peto","year":"1977","journal-title":"Br. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: Progress through collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11899-016-0337-y","article-title":"Treatment of childhood acute lymphoblastic leukemia: Prognostic factors and clinical advances","volume":"11","author":"Vrooman","year":"2016","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/leu.2013.206","article-title":"Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011","volume":"28","author":"Olsson","year":"2013","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/leu.2010.275","article-title":"Integrated use of minimal residual disease clas-sification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia","volume":"25","author":"Waanders","year":"2011","journal-title":"Leukemia"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/13\/3283\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:42:52Z","timestamp":1760139772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/13\/3283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":20,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["cancers14133283"],"URL":"https:\/\/doi.org\/10.3390\/cancers14133283","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,5]]}}}